FDA approved Axsome Therapeutics’ Auvelity for agitation in Alzheimer’s disease patients. Axsome says up to 76% of people diagnosed with Alzheimer’s disease experience agitation, which means the approval targets a symptom affecting the majority of that patient population.
Agitation is among the most disruptive behavioral symptoms in Alzheimer’s, affecting patients and wearing out caregivers. Managing it hasn’t been straightforward; clinicians have historically relied on off-label approaches in the absence of a labeled FDA option. Auvelity’s approval gives prescribers a drug they can write specifically for the indication, opening reimbursement and formulary pathways that didn’t exist before.
Auvelity was already on the market for a separate indication before this approval. The addressable population here, by Axsome’s own count, is most people living with Alzheimer’s today. The commercial case just got bigger. With the approval in hand, Axsome can now pursue formulary placement and payor contracts that weren’t available for an off-label use.
Sarah Chen